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Abstract
Genomic imprinting results in parent-of-origin-dependent monoallelic gene expression. Early work showed that distal
mouse chromosome 2 is imprinted, as maternal and paternal duplications of the region (with corresponding paternal and
maternal deficiencies) give rise to different anomalous phenotypes with early postnatal lethalities. Newborns with maternal
duplication (MatDp(dist2)) are long, thin and hypoactive whereas those with paternal duplication (PatDp(dist2)) are chunky,
oedematous, and hyperactive. Here we focus on PatDp(dist2). Loss of expression of the maternally expressed Gnas
transcript at the Gnas cluster has been thought to account for the PatDp(dist2) phenotype. But PatDp(dist2) also have two
expressed doses of the paternally expressed Gnasxl transcript. Through the use of targeted mutations, we have generated
PatDp(dist2) mice predicted to have 1 or 2 expressed doses of Gnasxl, and 0, 1 or 2 expressed doses of Gnas. We confirm
that oedema is due to lack of expression of imprinted Gnas alone. We show that it is the combination of a double dose of
Gnasxl, with no dose of imprinted Gnas, that gives rise to the characteristic hyperactive, chunky, oedematous, lethal
PatDp(dist2) phenotype, which is also hypoglycaemic. However PatDp(dist2) mice in which the dosage of the Gnasxl and
Gnas is balanced (either 2:2 or 1:1) are neither dysmorphic nor hyperactive, have normal glucose levels, and are fully viable.
But PatDp(dist2) with biallelic expression of both Gnasxl and Gnas show a marked postnatal growth retardation. Our results
show that most of the PatDp(dist2) phenotype is due to overexpression of Gnasxl combined with loss of expression of Gnas,
and suggest that Gnasxl and Gnas may act antagonistically in a number of tissues and to cause a wide range of phenotypic
effects. It can be concluded that monoallelic expression of both Gnasxl and Gnas is a requirement for normal postnatal
growth and development.
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Introduction
Early work showed that certain chromosomal regions can lead
to developmental abnormalities when both copies are exclusively
maternally or paternally derived. Distal mouse chromosome 2 was
one of the first such imprinting regions described, providing
evidence that imprinting must affect expression of some genes
according to parental origin [1]. Mice with two maternally derived
copies of the region but no paternally derived ones, MatDp(dist2),
had long thin bodies, failed to suckle, became inert and died within
a few hours of birth. On the other hand, mice with two paternally
derived copies of the region, but none that were maternally
derived, PatDp(dist2), had an apparently opposite phenotype for
they had short square bodies, (probably due to the combined
effects of oedema and a chunky body shape), were notably
hyperactive and died within a few days of birth. Hyperactivity may
not be evident at birth but generally developed during the day of
birth and became more pronounced in following days. In addition
many PatDp(dist2) mice have an unusual front foot movement
described as paddle feet, and a tail kink characteristically occurring
about halfway down the tail [1,2]. From genetic approaches using
reciprocal translocations the region on mouse chromosome 2
giving rise to these imprinting effects was estimated to be 7 Mb in
size and contained the Gnas cluster [3].
Misexpression of transcripts at the imprinted Gnas cluster can
account for much of the phenotype in both MatDp(dist2) and
PatDp(dist2). Gnas is a complex imprinted gene cluster with three
promoter regions that give rise to protein coding transcripts Nesp,
Gnasxl and Gnas. Each of these transcripts has a unique first exon
that splices on to a common set of downstream exons (Figure 1).
Nesp is exclusively expressed from the maternal allele and Gnasxl
from the paternal allele. Gnas is biallelically expressed in most
tissues but is preferentially maternally expressed in some [4,5,6,7].
Nesp gives rise to NESP55, neuroendocrine secretory protein 55,
Gnas to Gsa, the alpha subunit of the Gs signalling protein and
Gnasxl to XLas, a variant form of Gsa which can also function as
the alpha subunit of the heterotrimeric Gs protein. Both XLas and
Gsa can act on adenylyl cyclase to induce cyclic AMP production
[8]. Although XLas and Gsa share biochemical properties there is
evidence that they act antagonistically and have opposite effects on
metabolic regulation [9,10,11]. Overall the effects of paternally
expressed Gnasxl in offspring result in increased demands on the
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mother (growth promoting) whereas the effects of maternally
expressed Gnas result in fewer demands, in accordance with the
conflict hypothesis [12].
Imprinted expression of protein coding transcripts at the Gnas
cluster is controlled by an imprinting control region (ICR), a
germline differentially methylated region called the Nespas DMR
that covers the promoter of a noncoding antisense transcript,
Nespas [13]. The Nespas DMR is part of a larger DMR that covers
the Gnasxl promoter [14]). Paternal inheritance of the Nespastm1Jop
allele (hereafter called DNespas), a deletion of the Nespas DMR,
results in loss of imprinting of Nesp and Gnas, and down regulation
of Gnasxl [13]. The tissue specific imprinted expression of the Gnas
transcript is controlled by a second differentially methylated
region, the Exon 1A DMR that lies just upstream of Gnas exon 1
[15]. Paternal inheritance of the Gnastm1Jop allele (hereafter called
DEx1A), a deletion of the Exon 1A DMR, results in loss of
imprinted expression of Gnas and so the Exon 1A DMR solely
regulates the imprinted expression of Gnas [6,16]. Thus the Nespas
DMR must interact with the Exon 1A DMR to control the
imprinted expression of Gnas although the mechanism of
interaction is not yet clear.
PatDp(dist2) mice have two expressed copies of Gnasxl but lack
expression of Gnas in imprinted tissues and also lack expression of
Nesp [6,13,17] whereas MatDp(dist2) mice have two expressed
copies of Gnas in imprinted tissues and two expressed copies of Nesp
but lack expression of Gnasxl. PatDp(dist2) mice have greatly
diminished expression of Gnas in newborn brown fat consistent
with imprinted expression [6] and elevated levels of Gnasxl
consistent with two expressed doses [13].
From studies of targeted deletions and an ENU induced
mutation it is evident that both XLas and Gsa play important
roles in growth, behaviour and survival shortly after birth, but
NESP55 does not [7,9,10,18,19]. Paternal inheritance of a null
mutation in Gnasxl results in newborns with severely reduced
suckling ability that become inert on the day of birth and most die
within within a few days of birth [10]. Thus loss of expression of
Gnasxl can account for much of the phenotype observed in
MatDp(dist2) mice. On the other hand, maternal transmission of a
null mutation resulting in loss of Gnas transcript gives rise to
neonates with oedema and square shaped bodies, most of which
die before weaning [7,9] and maternal inheritance of a loss of
function allele, GnasOedsml-mat, (Oed), results in gross neonatal
oedema and pre-weaning lethality [18]. PatDp(dist2) are oedem-
atous at birth [1,20] (but the oedema is of considerably less severity
than in Oed mice) [18] and oedema may account for at least part of
the original description of a square shaped body [1,21]. Thus the
phenotype of mutants affecting Gsa function or expression has
some similarity to that seen in PatDp(dist2). But, neither the null
nor the loss of function mutation results in the hyperactivity shortly
after birth that is probably the most distinctive feature of
PatDp(dist2). So loss of maternal expression of Gnas transcripts
in imprinted tissues can account for the oedematous phenotype
seen in PatDp(dist2) mice but cannot account for the hyperactivity.
Thus hyperactivity may be due to a double dose of Gnasxl alone or
to the combined effect of a double dose of Gnasxl and loss of Gnas
in imprinted tissues.
We have used genetic approaches to show the combination of
over expression of Gnasxl and loss of Gnas gives rise to an early
hyperactivity lethal phenotype. Furthermore when the expressed
dosage of Gnas and Gnasxl is balanced then PatDp(dist2) are neither
lethal nor hyperactive. Thus the dosage of Gnas and Gnasxl needs
to be balanced for long term survival and normal activity.
Furthermore PatDp(dist2) with balanced dosage but two doses of
both Gnasxl and Gnas have normal viability and activity but
preweaning growth retardation followed by catch up growth. Thus
it may be important to have a single dose of Gnasxl and Gnas for
normal development or there may be other genes involved in
determining the PatDp(dist2) phenotype.
Materials and Methods
Ethics Statement
All mouse studies were carried out in accordance with the
guidance issued by the Medical Research Council in ‘‘Responsi-
bility in the use of animals in bioscience research (May 2008)’’,
were approved by the MRC Harwell ethical review committee
and carried out under the authority of the UK Home Office
Figure 1. Summary of transcription and methylation at the Gnas cluster. Transcribed exons are shown as filled boxes and nontranscribed
exons as empty boxes. Nespas and Exon 1A give rise to noncoding transcripts. The arrows indicate the direction of transcription and a thin arrow
indicates low expression. The methylation status of the Exon 1A differentially methylated region (DMR) and the Nespas DMR (the imprinting control
region, ICR, for the cluster) is shown as plus signs for methylated and minus signs for unmethylated.
doi:10.1371/journal.pone.0065639.g001
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Project Licence numbers 30/1518, 30/2065 30/2526, and 30/
2642.
Mice
Paternal duplication (PatDp(dist2)) mice were generated by the
standard genetic method of intercrossing genetically marked
translocation heterozygotes and identifying PatDp(dist2) mice
with the aid of markers [22]. From these intercrosses up to 16% of
live births are expected to be PatDp(dist2) [23]. We used the
translocation T(2;8)26H, (T26H), which has a breakpoint on
chromosome 2 at the a, nonagouti locus [23] proximal to the Gnas
cluster.
To generate PatDp(dist2) with altered dosing of Gsa and XLas
we developed translocation stocks that were heterozygous for
DEx1A (T26H +/+ DEx1A) (maternal allele listed first), homozy-
gous for DEx1A (T26H DEx1A/+ DEx1A), heterozygous for
DNespas (T26H +/+ DNespas), and heterozygous for both DEx1A
and DNespas (T26H+DEx1A/+ DNespas +). PatDp(dist2) that were
either heterozygous for DEx1A, or homozygous for DEx1A, or
heterozygous for DNespas, or heterozygous for both DEx1A and
DNespas were generated by crossing T26H +/++females with
either TH26+/+ DEx1A, or T26H DEx1A/+ DEx1A or T26H +/+
DNespas or T26H+DEx1A/+ DNespas+males. For each cross,
reciprocal crosses were also set up to generate PatDp(dist2) with
wild-type alleles at DEx1A and/or DNespas. The genetic back-
ground of PatDp(dist2) mice was mixed but with major
contributions from C3H/HeH (circa 45%) and the Harwell LL
stock (circa 45%). Toe or tail clips were taken from offspring at
birth and these served as both biopsies for identification and for
genotyping. Offspring were genotyped for paternal duplication,
DEx1A and DNespas as previously described [6,13,22].
Phenotyping
Mice were classified for oedema, chunky appearance, activity,
tail kink, and paddle feet, a paddling motion of the front feet, by
daily visual observation from birth. Mice were removed from the
box and observed for 2–3 minutes.
RNA Analysis
Total RNA was extracted and northern analysis carried out as
described previously (6, 13). Riboprobes specific for the unique
first exons of Gnas and Gnasxl and for Actb have been previously
described (6, 13). Transcript levels were measured by phosphoi-
mager analysis and quantified as described previously (6,13).
Biochemical Analysis of Plasma
Truncal blood from mice up to one week of age was collected
using heparinised capillary tubes. Plasma was separated following
centrifugation at 7506g for 3 minutes and stored at 280uC.
Noradrenaline was measured in duplicate using an ELISA kit
(Labor Diagnostika Nord GmbH & Co.KG) according to the
manufacturer’s instructions. Blood glucose was measured using an
Alphatrak Veterinary Blood Glucose Monitoring Meter Kit
(Abbott) according to the manufacturer’s instructions. Insulin
and glucagon were measured using an ELISA kit (Mercodia)
according to the manufacturer’s instructions.
Weight and Body Mass Index
Mice were weighed weekly from birth and from 4 weeks the
length from the tip of the nose to the base of the tail was measured
weekly. Body mass index was calculated using the following
equation: weight (g)/(length (cm))2.
Metabolic Caging
At nine weeks the mice were individually housed in metabolic
cages for 24 h, during which time they had free access to a known
amount of food and water. After 24 h, the amount of food and
water consumed was measured along with the volume of urine
produced. After housing in metabolic cages the mice were
returned to their home cage. For a fuller protocol, see EMPRess
(the European Phenotyping Resource for Standardised Screens
from EUMORPHIA; http://empress.har.mrc.ac.uk).
Metabolic Rate Measurements
At 10 and 21 weeks of age the mice were investigated using
indirect calorimetry (Oxymax, Columbus Instruments, Columbus,
OH, USA). Mice were weighed and then individually housed in
the equipment for 24 h, with food and free access to water. After
testing, the mice were returned to their home cage. Indirect
calorimetry enabled measurement of oxygen consumption, carbon
dioxide production, respiratory exchange ratio and heat produc-
tion.
DEXA Analysis
At 17 weeks of age the mice were weighed and given a
recoverable anaesthetic prior to scanning using a General Electric
Medical Systems Lunar PIXImus II X-ray densitometer (Inside
Outside Sales, Fichburg, WI, USA), which allows the fat and lean
mass and bone density to be calculated. Mice were placed in a
heated box to aid recovery; once fully recovered, they were
returned to their home cage.
Statistical Analyses
Fisher’s exact test was used for comparisons of the incidence of
PatDps and the occurrence of phenotypic features. Student’s t test
(two-tailed) was used for assessing the results of the growth and
metabolism studies and expression levels on northern blots. P
values ,0.05 were considered significant.
Results
Incidence and Survival of PatDp(dist2)
PatDp(dist2) has two expressed doses of Gnasxl and severely
reduced expression of imprinted Gnas [6,13] and will hereafter be
referred to as PatDp(dist2)2:0. To produce PatDp(dist2) with
differing doses of Gnasxl and Gnas we utilised two mutants, DEx1A
and DNespas. DEx1A is a deletion of the Exon 1A DMR, the region
that regulates the imprinted expression of Gnas. On paternal
inheritance Gnas is completely derepressed on the paternal allele
[6]. Heterozygotes +/DEx1A (maternal allele listed first) show
normal survival to birth for they were generated at a frequency of
44.5% (of 231 neonates) which is not significantly different from
the expected 50% (P.0.05).The DNespasmutant allele is a deletion
of the promoter and first exon of Nespas, the ICR for the Gnas
cluster [13]. On paternal inheritance of DNespas Gnasxl is
downregulated to about 24% of wild type levels (Figure S1) and
Gnas is expressed to about 70% of wild type on the paternal allele.
Heterozygotes +/DNespas also show normal survival to birth [13].
Four crosses were set up to generate PatDp(dist2) mice with
altered dosing of Gnasxl and Gnas (Figure 2, Table 1). In Cross 1
PatDp(dist2) mice heterozygous for DEx1A were produced to
provide PatDp(dist2)2:1 with two predicted expressed doses of
Gnasxl and one expressed dose of Gnas. In Cross 2 PatDp(dist2)
mice homozygous for DEx1A were generated to produce
PatDp(dist2)2:2 with two predicted expressed doses of Gnasxl and
two doses of Gnas. Cross 3 gave rise to PatDp(dist2) mice
heterozygous for DNespas predicted to have slightly more than
Dosage Effects at the Gnas Cluster
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one expressed dose of Gnasxl and slightly less than one expressed
dose of Gnas, called PatDp(dist2)1:1. From Cross 4 PatDp(dist2)
arose that were compound heterozygotes for DEx1A and DNespas
predicted to have slightly more than one expressed dose of Gnasxl
and slightly less than two expressed doses of Gnas, called
PatDp(dist2)1:2. For each cross reciprocal crosses were also set
up resulting in PatDp(dist2)2:0.
Heterozygotes +/DEx1A were known to express two doses of
imprinted Gnas, and PatDp(dist2)2:1 and PatDp(dist2)1:1 to
express one dose of imprinted Gnas [6]. From northern analysis,
similar levels of Gnas were found in newborn brown fat from +/
DEx1A and PatDp(dist2)2:2 homozygous for DEx1A indicating that
PatDp(dist2)2:2 express two full doses of Gnas (Figure 3).
There were no significant differences in the incidence or
phenotypes of PatDp(dist2)2:0 from the reciprocal crosses and so
the data from these were pooled for the Control cross (Table 1,
Figure 2A). The incidence of PatDp(dist2)2:0 generated using the
T26H translocation was not significantly different from that found
previously [24]. There was no significant difference in the
incidence of PatDp(dist2)2:2 compared to PatDp(dist2)2:0, nor in
the incidence of PatDp(dist2)2:1 or PatDp(dist2)1:2, but the
incidence of PatDp(dist2)1:1 at birth was significantly greater than
PatDp(dist2)2:0 (P= 0.0394, (Fisher’s exact test, two tailed)
(Table 2).
It should be borne in mind that the incidence of PatDp(-
dist2)2:1, PatDp(dist2)1:1 and PatDp(dist2)1:2 is likely to be an
underestimate because of recombination between the TH26
breakpoint on chromosome 2 and the Gnas cluster which lie
21cM apart (www.informatics.jax.org) (May, 2012). Thus in Cross
1, the cross to generate PatDp(dist2)2:1, recombinants PatDp(-
dist2)2:0 and PatDp(dist2) 2:2 were found. In Cross 3, the cross to
generate PatDp(dist2)1:1, recombinants PatDp(dist2)2:0 and
PatDp(dist2)0:2 occurred. In Cross 4, the cross to generate
PatDp(dist2)1:2, recombinants PatDp(dist2)2:2 arose. All recom-
binants in Cross 2, the cross to generate PatDp(dist2)2:2, will be
identical and indistinguishable from non recombinant PatDp(-
dist2)2:2 (Table 2). In the absence of recombination 4 more
PatDp(2:1) were expected in Cross 1, 6 more PatDp(dist2)1:1 in
Cross 3 and 1 more PatDp(dist2)1:2 in Cross 4. Using the expected
numbers of PatDps that would have occurred in the absence of
recombination the incidence of PatDp(dist2)2:1 is also significantly
greater than PatDp(dist2)2:0 (P= 0.0259, (Fisher’s exact test, two
tailed)). Overall the results indicate that dosage of Gnasxl and Gnas
can affect survival of PatDp(dist2) to birth.
Interestingly a recombinant PatDp(dist2)0:2 homozygous for
DNespas that arose in Cross 3 had a normal phenotype and
survived for 6 months. This is probably because in such a mouse
the expected levels of Gnasxl expression would be nearly 50% of
the wild type level and this appears to be sufficient for viability.
In agreement with earlier work PatDp(dist2)2:0 generated using
the T26H translocation only survived for a few days [24].
However there was some increase in survival of PatDp(dist2)2:1
compared to PatDp(dist2)2:0 with a couple of PatDp(dist2)2:1
reaching 13 days but none survived to weaning (Table 2). For
PatDp(dist2)2:2 and PatDp(dist2)1:1 where the expressed doses of
Gnas and Gnasxl are expected to be in balance and in
PatDp(dist2)1:2 predicted to have one expressed dose of Gnasxl
and two expressed doses of Gnas, there was a remarkable increase
in survival with most PatDp(dist2)2:2, PatDp(dist2)1:1 and
PatDp(dist2)1:2 reaching weaning (Table 2). After weaning the
viability of many of these PatDp(dist2) was as good as their non
PatDp(dist2) littermates. Thus for long term survival relative
overexpression of Gnasxl is disadvantageous but overexpression of
imprinted Gnas is not.
Neonatal Phenotype
At birth the PatDp(dist2)2:0 mice had the typical phenotype
(Table 3). Thus, most were noted to be oedematous although
oedema is much less marked in PatDp(dist2)2:0 than in the Oed
mutant, a point mutation in Gnas exon 6 [18,25]. Most
PatDp(dist2)2:0 were described as chunky and over 90% were
observed to be hyperactive within 24 hours of birth. The
hyperactivity is very distinctive. Whereas non PatDp mice move
very little shortly after birth, PatDp(dist2)2:0 tend to be in motion
most of the time, circling or crawling, often rapidly, with the
forelimbs showing a paddling motion (paddle feet). They
frequently fall on their backs and thrash around but are able to
right themselves. The hyperactive behaviour becomes more
extreme with the passing days (Video S1, S2). About half were
noted to have a tail kink and paddle feet. The occurrence of each
of these features is highly significant (P,0.0001, Fisher’s exact test,
two tailed) for none of these features was observed in the 351 non
duplication mice generated in the cross.
Of note, none of the PatDp mice with either one or two doses of
Gnas, thus PatDp(dist2)2:1, PatDp(dist2)2:2, PatDp(dist2)1:1 or
PatDp(dist2)1:2 were oedematous (Table 3). As oedema is known
to be associated with loss of functional imprinted Gnas in the
presence of a single expressed dose of Gnasxl [7,9,25,26] it can be
concluded that the oedema seen in PatDp(dist2)2:0 is attributable
to lack of expression of Gnas in tissues in which it is imprinted and
not to overexpression of Gnasxl.
Even though oedema was absent in PatDp(dist2)2:1, a number
were noted to be chunky (Table 3), indicating that oedema and a
chunky appearance are probably two separate components of the
short square body shape phenotype seen in PatDp(dist2)2:0 [1].
There was also a diminution in the number of PatDp(dist2)2:1,
PatDp(dist2)2:2, PatDp(dist2)1:1 and PatDp(dist2)1:2 described as
chunky compared to PatDp(dist2)2:0. In addition, fewer PatDp(-
dist2)2:2 and PatDp(dist2)1:1 were chunky compared to PatDp(-
dist2)2:1 (Table 3). Overall these results indicate that a double dose
of expressed Gnasxl together with loss of expression of imprinted
Gnas gives rise to this phenotype. However, if the double dose of
Gnasxl is matched with a double dose of Gnas the chunky
phenotype was not seen. For normality the expressed doses of
Gnasxl and Gnas need to be balanced (Table 3).
Hyperactivity in PatDp(dist2)2:0 although manifested on the
day of birth, becomes fully developed by the next day (Table 3).
There was a decrease in the incidence of hyperactivity in
PatDp(dist2)2:1, PatDp(dist2)2:2, PatDp(dist2)1:1 and PatDp(-
dist2)1:2 both on the day of birth and the following day. By day
2 almost all PatDp(dist2)2:0 were hyperactive but hyperactivity
was virtually absent in PatDp(dist2)2:2, PatDp(dist2)1:1 and
PatDp(dist2)1:2. A single PatDp(dist2)1:1 was found to be
hyperactive on day two, but appeared normal by day four and
this mouse was also classified as chunky. These findings were
unexpected as Gnas and Gnasxl have the same predicted expressed
dosage in PatDp(dist2)1:1 as in wild type. Loss of functional
imprinted Gnas in the presence of a single expressed dose of Gnasxl
is not associated with hyperactivity in the first few days of life
[7,18] although tremor and ataxia starting at around one week of
age have been observed in one Gnas knockout model [7]. On the
other hand hyperactivity in the first few days has been observed in
another mutant which like PatDp(dist2)2:0 has a double dose of
Gnasxl and loss of Gnas in imprinted tissues [27]. Overall the results
indicate that overexpression of Gnasxl combined with loss of
imprinted Gnas expression is responsible for the hyperactivity
phenotype.
The incidences of tail kink and paddle feet, both known features
of PatDp(dist2)2:0, are not significantly different in PatDp(dist2)2:1
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but are reduced in PatDp(dist2)2:2, PatDp(dist2)1:1 and PatDp(-
dist2)1:2. Furthermore, fewer PatDp(dist2)2:2 and PatDp(dist2)1:1
exhibited either tail kink and/or paddle feet than PatDp(dist2)2:1
(Table 3). Overall these results indicate that a double dose of
expressed Gnasxl together with either loss of, or a single dose of
imprinted Gnas gives rise to this phenotype. For normality the
expressed doses of Gnasxl and Gnas need to be balanced (Table 3).
Thus oedema can be attributed to lack of expression of Gnas in
tissues in which it is imprinted, chunkiness, hyperactivity, tail kink
and paddle feet to overexpression of Gnasxl, combined with loss of
imprinted Gnas expression.
Altered Metabolism in Neonatal PatDp(dist2)2:0 but not
PatDp(dist2)2:2
Studies of metabolism were undertaken in PatDp(dist2)2:0 and
and PatDp(dist2)2:2 and their nonduplication litttermates. The
nonduplication littermates of PatDp(dist2)2:0 are wild type for
DEx1A whereas nonduplication littermates of PatDp(dist2)2:2 are
heterozygous +/DEx1A and thus have biallelic Gnas expression.
We tested neonates for glucose and key hormones involved in
energy homeostasis (Figure 4). In PatDp(dist2)2:0 blood glucose
was considerably reduced and accordingly, plasma insulin was also
low compared to their nonduplication sibs. Furthermore, the
plasma glucagon level, expected to be raised in response to
hypoglycaemia, was under half that found in nonduplication +/+
sibs. Plasma noradrenaline levels, expected to be raised in response
to hypoglycaemia were elevated by more than 60% in PatDp(-
dist2)2:0. In contrast PatDp(dist2)2:2 had normal levels of glucose,
insulin, glucagon and noradrenaline. Thus there is an overall
disruption in glucose metabolism in PatDp(dist2)2:0 attributable to
overexpression of Gnasxl combined with loss of expression of Gnas.
Loss of Gnasxl expression in Gnasxlm+/p2 pups also results in
hypoglycaemia but, surprisingly no elevation of plasma noradren-
aline in newborns [10]. In the current study plasma noradrenaline
was measured in 2 and 3 day old pups (P2 and P3) and no
statistically significant difference was found in Gnasxlm+/p2 and
wild type littermates. The combined data for P2 & P3 were:
6.57 ng/ml 60.67 versus 8.8561.50; WT versus Gnasxlm+/p2;
mean6s.e.m; n = 14 WT and 9 Gnasxlm+/p2; P= 0.19).
In newborn +/DEx1A the levels of glucose, insulin and glucagon
and noradrenaline were not significantly different from wild type
indicating that overexpression of Gnas is not associated with altered
glucose metabolism.
Both PatDp(dist2)2:2 and +/DEx1A Mice Show Postnatal
Growth Retardation
Further studies from birth to adulthood of PatDp(dist2)2:2 and
their nonduplication +/DEx1A sibs were carried out. In addition
studies of +/DEx1A and their +/+ sibs from a cross of C3H/HeH
females to +/DEx1A males were undertaken. For weight studies
between birth and weaning the weights of both sexes were
combined as no significant differences in the weights of males and
females were found, and after weaning only males were used. Mice
were weighed on the day of birth and weekly thereafter.
The weights are shown as a percentage of their wild type
siblings (Figure 5). The +/DEx1A mice were lighter at birth, 90.1%
(P= 0.021), of the weight of their wild type siblings, indicating
prenatal growth retardation. Growth retardation became more
pronounced during the first week of life but by weaning +/DEx1A
had started to catch up so that by nine weeks their weight was no
longer significantly different from wild type (Figure 5A). Similar
findings of prenatal and preweaning growth retardation followed
by catch up growth has been reported on paternal inheritance of
the Ex1A-T-CON allele which also results in loss of imprinted
expression of Gnas [28].
PatDp(dist2)2:2 were generated by Cross 2, T26H++/+++ X
T26H+DEx1A/++DEx1A so all the nonduplication sibs were
heterozygous for DEx1A. PatDp(dist2)2:2 did not differ in weight
from their nonduplication +/DEx1A sibs at birth or at one week of
age indicating that PatDp(dist2)2:2 were also growth retarded and
to the same extent as +/DEx1A. By two weeks of age
PatDp(dist2)2:2 were even lighter in weight than +/DEx1A and
continued to weigh less than +/DEx1A until 6 weeks but
subsequently did not differ significantly in weight from +/DEx1A.
Thus postnatal growth retardation in PatDp(dist2)2:2 peaked at
three weeks and was followed by catch up growth (Figure 5B).
Thus loss of imprinting of Gnas in +/DEx1A results in growth
retardation before weaning resulting in proportionately smaller
mice followed by catch up growth in adulthood. PatDp(dist2)2:2
with predicted balanced expressed dosage of Gnas and Gnasxl show
a more severe pre-adult growth retardation resulting in propor-
tionately smaller mice followed by catch up growth by 10–11
weeks of age and overall increased weight thereafter.
Figure 2. Transcript expression in PatDp(dist2). Summary of transcription and methylation at the Gnas cluster in (A) PatDp(dist2)2:0, (B)
PatDp(dist2)2:1, (C) PatDp(dist2)2:2 (D) PatDp(dist2)1:1, (E) PatDp(dist2)1:2. Transcribed exons are shown as filled boxes and nontranscribed exons or
exons giving rise to very markedly reduced levels of transcript as empty boxes. Nesp exon 1 is noncoding and Nespas and Exon 1A give rise to
noncoding transcripts. The arrows indicate the direction of transcription and a thin arrow indicates low expression. The methylation status of the
Exon 1A DMR and the Nespas DMR is shown as plus signs for methylated and minus signs for unmethylated.
doi:10.1371/journal.pone.0065639.g002
Table 1. Crosses to generate PatDp(dist2).
Cross Cross PatDp Genotype of PatDp Expected Ratio
Gnasxl: Gnas
Control cross T26H++/+++ X T26H++/+++ PatDp(dist2)2:0 T26H++/+++ 2:0
Cross 1 T26H++/+++ X T26H++/++DEx1A PatDp(dist2)2:1 T26H++/++DEx1A 2:1
Cross 2 T26H++/+++ X T26H +DEx1A/++DEx1A PatDp(dist2)2:2 T26H+DEx1A/++DEx1A 2:2
Cross 3 T26H++/+++ X T26H++/+ DNespas + PatDp(dist2)1:1 T26H++/+ DNespas + 1:1
Cross 4 T26H++/+++ X T26H+DEx1A/+ DNespas + PatDp(dist2)1:2 T26H +DEx1A/+ DNespas + 1:2
doi:10.1371/journal.pone.0065639.t001
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The body length of +/DEx1A mice, their wild type sibs, and
PatDp(dist2)2:2 and their +/DEx1A sibs was measured weekly
from 4 weeks. +/DEx1A mice were shorter (93.260.5% s.e.m of
the length of wild type sibs) than their wild type sibs at 4 weeks
(P,0.05, n = 4–11) but caught up in length by 10 weeks.
PatDp(dist2)2:2 were even shorter than +/DEx1A from 4 to 6
weeks (91.861.3% s.e.m at 4 weeks P= 0.00097, n= 10, and
96.861.2% s.e.m at 6 weeks P,0.022, n = 12) but thereafter did
not differ in length from +/DEx1A.
Body mass index, BMI was significantly lower in +/DEx1A than
wild type at 4 weeks (0.2960.004 s.e.m versus 0.3460.007 s.e.m;
P= 2.55E-05, n= 4–11) but did not differ from wild type
thereafter. No difference in BMI was found between +/DEx1A
and PatDp(dist2)2:2 (n = 10–12).
Analysis of 24h food intake at 10 weeks showed no difference in
+/DEx1A and wild type sibs (n = 4–14) or in +/DEx1A and
PatDp(dist2)2:2 (n = 10–12) (data not shown).
The results of DEXA analysis at 17 weeks indicated there were
no significant differences in fat or lean mass in +/DEx1A and wild
type sibs (n = 5–12) or in +/DEx1A and PatDp(dist2)2:2 (n = 9)
(data not shown).
+/DEx1A but not PatDp(dist2)2:2 have a Higher Metabolic
Rate
At 10 weeks of age +/DEx1A tended to show increased oxygen
consumption and carbon dioxide output in comparison with wild-
type littermates and these increases were statistically significant
(P,0.03) by 21 weeks of age in +/DEx1A mice indicative of a
raised metabolic rate (Figure 6).
Discussion
The oedema in PatDp(dist2)2:0 is likely to be due to loss of
expression of imprinted Gnas as oedema was not seen in
PatDp(dist2) in which Gnas expression was restored to normal.
This agrees with the results from other studies indicating that null
or loss of function mutations of Gnas are associated with neonatal
oedema [1,7,9,26,27,29] but neonatal oedema was not observed
when imprinted Gnas expression was restored to normal [6,30].
Oedema in PatDp(dist2)2:0 is known to develop from 12.5 dpc
and by late gestation PatDp(dist2)2:0 are severely oedematous and
Oed even more so with oedema declining somewhat in both genetic
conditions before birth [18,20]. The occurrence of oedema in utero
could conceivably affect survival to birth and so the restoration of
imprinted Gnas expression in PatDp(dist2)2:1 and PatDp(dist2)1:1
may account for their increased incidence at birth compared to
PatDp(dist2)2:0.
The other neonatal phenotypes of PatDp(dist2), namely
lethality, hyperactivity, paddle feet, chunky appearance, tail kink,
can be attributed to biallelic expression of Gnasxl combined with
loss of imprinted Gnas expression. A considerable improvement in
the incidence of newborns that were neither hyperactive nor
chunky and some improvement in survival to seven days was
found when biallelic expression of Gnasxl was combined with
normal monoallelic expression of Gnas in PatDp(dist2)2:1.
However, for full viability and loss of hyperactivity, biallelic
expression of Gnasxl needs to be balanced with biallelic expression
of imprinted Gnas or monoallelic expression of Gnasxl with
monoallelic expression of Gnas. This need for balanced dosage is
in accord with observations indicating that maternally expressed
Gnas and paternally expressed Gnasxl act antagonistically [10].
Interestingly monoallelic expression of Gnasxl combined with
biallelic, and thus overexpression of imprinted Gnas, in either
PatDp(dist2)1:2 or +/DEx1A results in normal viability. Normal
viability was also recently reported for the Ex1A-T-CON mutant in
which Gnas is overexpressed [28]. Thus overexpression of Gnas has
less drastic results on phenotype than overexpression of Gnasxl. But
in the presence of two expressed copies of Gnasxl it is critical to
have two expressed copies of Gnas in order to survive to weaning.
PatDp(dist2)2:0 are hyperactive and hypoglycaemic and both
these phenotypes may contribute to their early death. Hyperac-
tivity has also been reported for some DNesp55m neonates [27]
which like PatDp(dist2)2:0 have two expressed doses of Gnasxl and
no expressed doses of imprinted Gnas. The hyperactivity in
PatDp(dist2)2:0 and DNesp55m may reflect a central neurological
deficit. The finding of raised noradrenaline in PatDp(dist2)2:0
together with a recent report showing that Gnasxl is expressed in
neonatal muscle [31] may well have relevance for the hyperactivity
phenotype. Conversely the hypotonia and inactivity of Gnasxl KO
pups might be at least partly due to the lack of XLas in muscle.
PatDp(dist2)2:0 are hypoglycaemic with low insulin and raised
noradrenaline. DNesp55m neonates are also hypoglycaemic and
although poor feeding may well contribute to their hypoglycaemia
they may, in addition, have a defect in glucose counterregulation
[26]. The causes of the hypoglycaemia in PatDp(dist2)2:0 are not
known, and even though they have a milk spot they could have a
Figure 3. Gnas expression in newborn brown fat measured by
northern blotting. (A) Bar chart showing Gnas levels in PatDp(2:2)
normalised to b-actin mRNA and shown relative to the level in +/DEx1A.
Mean 6 sem calculated for 5 PatDp(dist2)2:2 and 8+/DEx1A. (B)
Northern blot of Gnas and b-actin loading control in +/DEx1A and
PatDp(2:2) using 5 mg total RNA from newborn brown fat.
doi:10.1371/journal.pone.0065639.g003
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feeding impairment that could contribute to the hypoglycaemia.
Also, in view of their low glucagon, PatDp(dist2)2:0 could have a
defect in glucose counterregulation. In PatDp(dist2)2:2 with
balanced expressed doses of both Gnasxl and Gnas, glucose
metabolism is restored to normal, suggesting that both Gnasxl
and imprinted Gnas have a role in neonatal glucose metabolism.
Both Gsa and XLas have several variants. Thus C-terminally
truncated neural specific forms GsaN1 and XLN1 of Gsa and
XLas respectively are known [32,33]. In addition XLas has a
second ORF that encodes a protein ALEX and then there is an N-
terminally extended form of XLas called XXLas [34,35,36]. On
comparison of the phenotypes seen in mouse models in which
different transcripts have been inactivated it appears that XLas/
XXLas play a part in growth and metabolism, ALEX may affect
suckling but roles for XLN1 and GsaN1 have not been established
yet [28,37]. Possibly the metabolic defects in PatDp(dist2)2:0 can
be attributed in part at least to overexpression of XLas/XXLas
but the contribution of the various Gnasxl proteins to other aspects
of the PatDp(dist2)2:0 phenotype is as yet unknown.
Our data indicate that both Gnas and Gnasxl have roles in the
phenotype of PatDp(dist2). Loss of the orthologous GNAS
transcript in humans is associated with a number of endocrine
and bone disorders including pseudohypoparathyroidism, Albright
Hereditary Ostedystrophy and progressive osseous heteroplasia
[38]. Pseudohypoparathyroidism type Ia (PHP-Ia) is due to
maternal inheritance of an inactivating mutation in GNAS and
pseudohypoparathyroidism type Ib is caused by defective
imprinting at the cluster (reviewed in [37]). In both conditions
there is resistance to parathyroid hormone but PHP-Ia is also
associated with multiple hormone resistance and Albright hered-
itary osteodystrophy (AHO). Some patients with PHP-Ib have
mild AHO features indicating overlap in the PHP-Ia and PHP-Ib
Table 2. Incidence and Survival of PatDp(dist2).
Cross PatDp Expected Ratio Incidence at birth Survival to 7d Survival to weaning
Gnasxl: Gnas No % No % No %
Control cross PatDp(dist2)2:0 2:0 31/428 7 3/28 8 0/28 0
Cross 1 PatDp(dist2)2:1 2:1 *18/171 10 5/14 36 0/14 0
Cross 2 PatDp(dist2)2:2 2:2 19/171 11 ,412/12 100 3,511/12 92
Cross 3 PatDp(dist2)1:1 1:1 , 131/258 12 3,419/21 90 3,519/21 90
Cross 4 PatDp(dist2)1:2 1:2 ‘6/73 8 2 5/6 83 3,4 5/6 83
*23 PatDp altogether but 2 were PatDp(dist2)2:2 and 3 were PatDp(dist2)2:0.
,36 PatDp altogether but 3 were PatDp(dist2)0:2 and 2 were PatDp(dist2)2:0.
‘10 PatDp altogether but 3 were PatDp(dist2)2:1 and one was not classified for DEx1A.
Incidence No shows the number of PatDps born/total number of mice born.
Survival No shows number of PatDps/total number of PatDps scored.
For comparison of PatDp(dist2)2:0 with other PatDp classes:
1P,0.05,
2P,0.01,
3P,0.0001 (Fisher’s exact test, 2 tailed).
For comparison of PatDp(dist2)2:1 with other PatDp classes except PatDp(dist2)2:0:
4P,0.002,
5P,0.0001 (Fisher’s exact test, 2 tailed).
doi:10.1371/journal.pone.0065639.t002
Table 3. Neonatal Phenotype of PatDp(dist2).
PatDp
Expected
Ratio Oedema Chunky Hyperactive Tail kink Paddle feet
Gnasxl: Gnas No % No % day 1 day 2 No % No %
No % No %
PatDp(dist2)2:0 2:0 22/25 88 20/24 83 14/21 67 15/16 93 12/20 60 11/20 55
PatDp(dist2)2:1 2:1 *0/14 0 ,5/14 36 ,2/13 15 *3/8 37 6/14 43 4/14 29
PatDp(dist2)2:2 2:2 *0/19 0 *20/19 0 *0/17 0 *1/12 8 *31/19 5 *3 0/19 0
PatDp(dist2)1:1 1:1 *0/28 0 *21/28 18 *0/28 0 *1/20 5 *32/28 7 *2/28 7
PatDp(dist2)1:2 1:2 *0/6 0 ,1/6 17 ,0/6 0 *0/6 0 ‘0/6 0 ‘0/6 0
For comparison of PatDp(dist2)2:0 with other PatDp classes:
*P,0.001;
,P,0.01,
‘P,0.05 (Fisher’s exact test, 2 tailed).
For comparison of PatDp(dist2)2:1 with other PatDp classes except PatDp(dist2)2:0:
2P,0.01;
3P,0.05 (Fisher’s exact test, 2 tailed).
No indicates number of PatDp with the phenotype/total number of PatDp classified.
doi:10.1371/journal.pone.0065639.t003
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Figure 4. Metabolic analyses in early postnatal stages. (A) blood glucose levels. (n = 9–10) (B) plasma insulin levels.(n = 10–14) (C) plasma
glucagon levels.(n = 9–13) (D) plasma noradrenaline. (n = 10–38). Error bars show standard errors of the means; ***P,0.001, **P,0.01, *P,0.05.
doi:10.1371/journal.pone.0065639.g004
Figure 5. Growth retardation. (A) Growth curve of +/DEx1A and wild-type littermates from 1 day to 12 weeks. The weights of wild-type
littermates have been normalised to 1 at each timepoint and the weights of +/DEx1A mice have been taken as a percentage of wild-type weights.
(n = 5–26). (B) Growth curve of PatDp(dist2)2:2 and +/DEx1A. The weights of +/DEx1A littermates have been normalised to 1 at each timepoint and
the weights of PatDp(dist2)2:2 mice have been taken as a percentage of +/Ex1A weights (n = 9–12). Error bars show standard errors of the means.
doi:10.1371/journal.pone.0065639.g005
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phenotypes [39,40,41,42,43]. Pseudohypoparathyroidism type Ib,
PHP-Ib, can occur sporadically or as an autosomal dominant. One
cause of the sporadic form is paternal uniparental disomy for
human chromosome 20 (patUPD20) and altogether there are
reports of eight patUPD20 patients with PHP-Ib [40,44,45,46,47].
The molecular consequences for patUPD20 appear to the similar
to those for PatDp(2:0) and are predicted to result in overexpres-
sion of GNASXL and loss of expression of GNAS in imprinted
tissues. Autosomal dominant PHP-Ib is caused by maternal
inheritance of microdeletions with microdeletions within the
GNAS cluster resulting in epigenetic changes leading to loss of
imprinted GNAS expression together with overexpression of
GNASXL or microdeletions upstream of the cluster resulting in
loss of imprinted GNAS expression alone [48,49,50,51]. Thus the
clinical features of PHP-Ib appear to be due to loss of imprinted
GNAS, and overexpression of GNASXL does not appear to play a
significant role in the phenotype. However two of the patUPD20
patients showed neonatal hypoglycaemia [40,45] which, in view of
the findings in PatDp(dist2)2:0 in the mouse, could be due to
overexpression of GNASXL. In neonatal PatDp(dist2) mice
hyperactivity commencing shortly after birth and elevated
noradrenaline are also features of raised Gnasxl levels. It would
be of interest to ascertain if metabolism and activity in PHP-Ib
patients are affected in the early postnatal period and if so,
whether elevated GNASXL is responsible.
We have shown that loss of imprinting of Gnas in +/DEx1A
results in postnatal growth retardation followed by catch up
growth and can be attributed solely to loss of imprinting, resulting
in biallelic expression, of Gnas. The effects on postnatal growth in
+/DEx1A parallel the growth pattern seen in +/Ex1A-T-CON mice
which also have loss of imprinting of Gnas [28]. Thus maternally
expressed Gnas clearly has a role in growth. Paternally expressed
Gnasxl is also known to affect postnatal growth and mutations
resulting in loss of functional Gnasxl also result in postnatal growth
retardation [7,10,11,18,28,29,52] The finding that both overex-
pression of Gnas and underexpression of Gnasxl results in growth
retardation accords with the parental conflict theory that predicts
that maternally expressed imprinted genes will be growth
inhibiting and paternally expressed imprinted genes will be growth
enhancing [12]. Thus it was expected that postnatal growth would
be unaffected in PatDp(dist2)2:2 mice which have a predicted
balanced dosage of Gnas and Gnasxl. However PatDp(dist2)2:2
mice show a more extreme postnatal growth retardation than seen
with overexpression of Gnas in +/DEx1A. Thus biallelic expression
of both Gnas and Gnasxl has resulted in postnatal growth
retardation. One interpretation is that it is important to have
monoallelic expression of antagonistic Gnasxl and Gnas for normal
growth. The advantages of monoallelic expression of both Gnasxl
and Gnas must outweigh the costs associated with functional
haploidy.
Supporting Information
Figure S1 Expression of Gnasxl was reduced on pater-
nal inheritance of DNespas. (A) Northern blot of Gnasxl and b-
actin loading control using 2.5 mg of poly (A)+ RNA from 15.5-dpc
embryos. MatDp(dist2) have no expressed copies of Gnasxl, whilst
PatDp(dist2) have two expressed copies, leading to the absence of
the 2.5 kb band and the presence of a strong 2.5 kb band
respectively. (B) Bar chart showing the Gnasxl expression levels in
+/DNespas (mean 6 s.e.m 2463.56%) were decreased on
comparison to wild-type (+/+) (mean 6 s.e.m 10369.39%)
*P= 0.005 (Student’s t test, two-tailed). The mean 6 s.e.m was
calculated for 3 wild-type (+/+) and four +/DNespas.
(TIF)
Video S1 Hyperactivity in PatDp(dist2). Video of a 6 day
old PatDp(dist2) and wild-type littermate showing almost continual
activity and rapid movement with paddling of the front feet in the
PatDp(dist2) but very little movement in the wild-type. The
PatDp(dist2) has the characteristic tail kink or bend, and by 6 days
is clearly smaller than the wild-type but oedema and a chunky
appearance are no longer evident. The mice have a genetic
background that is 50% Mus musculus castaneus and 50% laboratory
mouse. On this background there was slightly better survival of
PatDp(dist2) to 7 days (10/23) compared with 3/28 on an entirely
Figure 6. Metabolic rate. Analysis of metabolic rate in 21 week old
male +/DEx1A and their wild-type littermates, and PatDp(dist2)2:2 and
their +/DEx1A littermates. (A) and (B) Rates of oxygen consumption and
carbon dioxide output respectively (n = 4–12). Error bars show standard
errors of the means; **P,0.01, *P,0.05.
doi:10.1371/journal.pone.0065639.g006
Dosage Effects at the Gnas Cluster
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e65639
laboratory mouse background (P= 0.0106 (Fisher’s exact test, 2-
tailed) but no difference in survival to weaning.
(MP4)
Video S2 Hyperactivity in PatDp(dist2). Video of the same
PatDp(dist2) and wild-type littermate at 6 days as in Video S2 and
the PatDp(dist2) at 5 days of age on its own. The video shows the
ability of the PatDp(dist2) to right itself after falling on its back, as
well as its continual activity and rapid movement.
(MP4)
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